Cadila Pharma shuts formulations unit after spate of coronavirus cases at plant

A senior government official said that five employees had tested positive for COVID-19 six days back, while 21 others tested positive this week.

Cadila Pharmaceuticals shut down its formulations manufacturing plant in Ahmedabad recently after more than two dozen of its employees tested positive for the new coronavirus.

A senior government official said that five employees had tested positive for COVID-19 six days back, while 21 others tested positive this week.

“We had collected samples of 30 employees of Cadila on 5th May, 2020 and 21 of the samples returned positive a day later,” said Arun Mahesh Babu, District Development Officer, Ahmedabad.

He added the plant was ordered to be shut down and 95 employees had been quarantined and sanitisation work at the site had begun.

The incident comes just days after India began to ease some of its lockdown restrictions aimed at preventing the spread of the new coronavirus. Ahmedabad, however, is one of the more badly affected cities in India and has moved to tighten restrictions this week.

In a statement, Cadila Pharmaceuticals said, “Recently, 26 of our employees from our Dholka manufacturing facility tested positive for COVID-19. Following this, we have closed our operations on our own.”

The company also said it is cooperating with the local administration to ensure the safety and security of its facility and surroundings.

Besides Dholka, Cadila Pharmaceuticals has manufacturing facilities in other parts of India and in Ethiopia. The company is a major producer of active pharmaceutical ingredients (API) – the key ingredients used in making a drug.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.